P D Senter

Summary

Affiliation: Seattle Genetics
Country: USA

Publications

  1. ncbi request reprint Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs
    Brian E Toki
    Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
    J Org Chem 67:1866-72. 2002
  2. doi request reprint The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Seattle Genetics, Bothell, Washington, USA
    Nat Biotechnol 30:631-7. 2012
  3. doi request reprint Potent antibody drug conjugates for cancer therapy
    Peter D Senter
    Seattle Genetics, Inc, 21823 30th Dr SE, Bothell, WA 98021, United States
    Curr Opin Chem Biol 13:235-44. 2009
  4. ncbi request reprint Drug carriers in medicine and biology
    Peter D Senter
    Seattle Genetics, Bothell, Washington 98021, USA
    Mol Pharm 1:395-8. 2004
  5. ncbi request reprint Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug
    P D Senter
    Seattle Genetics, Inc 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 12:1074-80. 2001
  6. ncbi request reprint Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates
    P D Senter
    Seattle Genetics, 21823 30th Dr SE, Bothell, WA 98021, USA
    Adv Drug Deliv Rev 53:247-64. 2001
  7. ncbi request reprint Dipeptide-based highly potent doxorubicin antibody conjugates
    Scott C Jeffrey
    Department of Chemistry, Seattle Genetics, 21823 30th Drive SE, Bothell, WA 98021, USA
    Bioorg Med Chem Lett 16:358-62. 2006
  8. ncbi request reprint Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
    Svetlana O Doronina
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 17:114-24. 2006
  9. ncbi request reprint Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
    May S Kung Sutherland
    Department of Molecular Oncology and Immunology, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Biol Chem 281:10540-7. 2006
  10. ncbi request reprint Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 66:2328-37. 2006

Collaborators

Detail Information

Publications37

  1. ncbi request reprint Protease-mediated fragmentation of p-amidobenzyl ethers: a new strategy for the activation of anticancer prodrugs
    Brian E Toki
    Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
    J Org Chem 67:1866-72. 2002
    ..This result extends the use of the self-immolative p-aminobenzyl group for the fragmentation of aromatic ethers and provides a new strategy for anticancer prodrug development...
  2. doi request reprint The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma
    Peter D Senter
    Seattle Genetics, Bothell, Washington, USA
    Nat Biotechnol 30:631-7. 2012
    ..Research is under way to extend the applications of brentuximab vedotin and to advance the field by developing other ADCs with new linker and conjugation strategies...
  3. doi request reprint Potent antibody drug conjugates for cancer therapy
    Peter D Senter
    Seattle Genetics, Inc, 21823 30th Dr SE, Bothell, WA 98021, United States
    Curr Opin Chem Biol 13:235-44. 2009
    ..This review details many of the technological advancements, and provides examples of promising ADCs that are currently in clinical trials...
  4. ncbi request reprint Drug carriers in medicine and biology
    Peter D Senter
    Seattle Genetics, Bothell, Washington 98021, USA
    Mol Pharm 1:395-8. 2004
  5. ncbi request reprint Identification and activities of human carboxylesterases for the activation of CPT-11, a clinically approved anticancer drug
    P D Senter
    Seattle Genetics, Inc 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 12:1074-80. 2001
    ..These results confirm the importance of hCE-2 for CPT-11 activation and underscore the importance of enzyme kinetics for selective prodrug activation...
  6. ncbi request reprint Selective activation of anticancer prodrugs by monoclonal antibody-enzyme conjugates
    P D Senter
    Seattle Genetics, 21823 30th Dr SE, Bothell, WA 98021, USA
    Adv Drug Deliv Rev 53:247-64. 2001
    ....
  7. ncbi request reprint Dipeptide-based highly potent doxorubicin antibody conjugates
    Scott C Jeffrey
    Department of Chemistry, Seattle Genetics, 21823 30th Drive SE, Bothell, WA 98021, USA
    Bioorg Med Chem Lett 16:358-62. 2006
    ..The approaches described here for attaching highly potent doxorubicin derivatives to mAbs are novel and allow for control of drug stability while covalently bound to the delivery agent...
  8. ncbi request reprint Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: effects of linker technology on efficacy and toxicity
    Svetlana O Doronina
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 17:114-24. 2006
    ..Thus, alterations of the linker have pronounced impacts on toxicity and lead to new ADCs with greatly improved therapeutic indices...
  9. ncbi request reprint Lysosomal trafficking and cysteine protease metabolism confer target-specific cytotoxicity by peptide-linked anti-CD30-auristatin conjugates
    May S Kung Sutherland
    Department of Molecular Oncology and Immunology, Seattle Genetics Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Biol Chem 281:10540-7. 2006
    ....
  10. ncbi request reprint Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates
    Che Leung Law
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer Res 66:2328-37. 2006
    ....
  11. ncbi request reprint CR011, a fully human monoclonal antibody-auristatin E conjugate, for the treatment of melanoma
    Kam Fai Tse
    CuraGen, Branford, Connecticut 06405, USA
    Clin Cancer Res 12:1373-82. 2006
    ..We sought to identify melanoma-associated cell surface molecules and to develop as well as preclinically test immunotherapeutic reagents designed to exploit such targets...
  12. ncbi request reprint Characterization of a CC49-based single-chain fragment-beta-lactamase fusion protein for antibody-directed enzyme prodrug therapy (ADEPT)
    Ralph F Alderson
    Genencor International, a Danisco company, 925 Page Mill Road, Palo Alto, California 94304, USA
    Bioconjug Chem 17:410-8. 2006
    ..5, in combination with a novel prodrug, GC-Mel, resulted in significant efficacy in a colorectal xenograft tumor model and supports the utility of the protein as an agent for tumor-selective prodrug activation...
  13. ncbi request reprint Potent antitumor activity of an auristatin-conjugated, fully human monoclonal antibody to prostate-specific membrane antigen
    Dangshe Ma
    PSMA Development Co LLC, Tarrytown, New York, USA
    Clin Cancer Res 12:2591-6. 2006
    ..Importantly, 40% of treated animals had no detectable tumor or measurable PSA at day 500 and could be considered cured. The findings support development of PSMA antibody-auristatin conjugates for therapy of prostate cancer...
  14. ncbi request reprint Development and properties of beta-glucuronide linkers for monoclonal antibody-drug conjugates
    Scott C Jeffrey
    Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 17:831-40. 2006
    ..75 mg/kg. These results demonstrate that the beta-glucuronide linker system is an effective strategy for targeting cytotoxic agents providing ADCs with high degrees of efficacy at well-tolerated doses...
  15. ncbi request reprint Minor groove binder antibody conjugates employing a water soluble beta-glucuronide linker
    Scott C Jeffrey
    Seattle Genetics Inc, 21823 30th Drive S E, Bothell, WA 98021, USA
    Bioorg Med Chem Lett 17:2278-80. 2007
    ..The water soluble beta-glucuronide linker is stable in plasma and effectively delivers drugs to target cells leading to potent cytotoxic activities...
  16. ncbi request reprint Treatment parameters modulating regression of human melanoma xenografts by an antibody-drug conjugate (CR011-vcMMAE) targeting GPNMB
    Vincent A Pollack
    Department of Preclinical Development, CuraGen Corporation, 322 E Main St, Branford, CT 06405, USA
    Cancer Chemother Pharmacol 60:423-35. 2007
    ....
  17. ncbi request reprint Improved efficacy of alphavbeta3-targeted albumin conjugates by conjugation of a novel auristatin derivative
    Kai Temming
    Department of Pharmacokinetics and Drug Delivery, University Center for Pharmacy, University of Groningen, Groningen, The Netherlands
    Mol Pharm 4:686-94. 2007
    ....
  18. doi request reprint Contribution of linker stability to the activities of anticancer immunoconjugates
    Stephen C Alley
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, WA 98021, USA
    Bioconjug Chem 19:759-65. 2008
    ..In summary, the data indicate that new linkers can be obtained with improved in vivo stability by replacing the maleimide with an acetamide, but the resulting ADCs had similar tolerability and activity profiles...
  19. doi request reprint Antibody-drug conjugates for cancer therapy
    Paul J Carter
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Cancer J 14:154-69. 2008
    ..This review details these advances, discusses some of the remaining challenges, and overviews ADCs currently in clinical trials for cancer therapy...
  20. pmc Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides
    Michael M C Sun
    Seattle Genetics, Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 16:1282-90. 2005
    ..The resulting conjugates are highly active both in vitro and in vivo and are well tolerated at efficacious doses...
  21. ncbi request reprint Arming antibodies: prospects and challenges for immunoconjugates
    Anna M Wu
    Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at University of California, Los Angeles, Box 951770, 700 Westwood Plaza, Los Angeles, California 90095, USA
    Nat Biotechnol 23:1137-46. 2005
    ..Nonetheless, highly promising results from preclinical models will continue to drive the clinical development of this therapeutic class...
  22. ncbi request reprint Reductively activated disulfide prodrugs of paclitaxel
    Vivekananda M Vrudhula
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Bioorg Med Chem Lett 12:3591-4. 2002
    ..These compounds behaved as prodrugs in vitro on L2987 lung carcinoma cells. In vivo evaluation in mice demonstrated that the mutual prodrug 5 with captopril exhibited significant regressions and cures...
  23. ncbi request reprint Cephalosporin prodrugs of paclitaxel for immunologically specific activation by L-49-sFv-beta-lactamase fusion protein
    Vivekananda M Vrudhula
    Bristol Myers Squibb Pharmaceutical Research Institute, 5 Research Parkway, Wallingford, CT 06492, USA
    Bioorg Med Chem Lett 13:539-42. 2003
    ..Immunologically specific activation of the prodrug 5 containing 3,3-dimethyl-4-amino-butyric acid as linker in combination with the fusion protein L-49-sFv-beta-lactamase was demonstrated in vitro on 3677 melanoma cells...
  24. ncbi request reprint cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity
    Joseph A Francisco
    Seattle Genetics, Bothell, WA 98021, USA
    Blood 102:1458-65. 2003
    ..Mice treated at 30 mg/kg cAC10-vcMMAE showed no signs of toxicity. These data indicate that cAC10-vcMMAE may be a highly effective and selective therapy for the treatment of CD30+ neoplasias...
  25. ncbi request reprint Development of potent monoclonal antibody auristatin conjugates for cancer therapy
    Svetlana O Doronina
    Seattle Genetics, Inc, 21823 30th Dr SE, Bothell, Washington 98021, USA
    Nat Biotechnol 21:778-84. 2003
    ..These conjugates illustrate the importance of linker technology, drug potency and conjugation methodology in developing safe and efficacious mAb-drug conjugates for cancer therapy...
  26. ncbi request reprint Improved yield and stability of L49-sFv-beta-lactamase, a single-chain antibody fusion protein for anticancer prodrug activation, by protein engineering
    Charlotte F McDonagh
    Seattle Genetics Inc, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 14:860-9. 2003
    ..These results show that a rational protein-engineering approach improved the yield, stability, and refolding characteristics of L49-sFv-bL while maintaining binding affinity and therapeutic efficacy...
  27. ncbi request reprint Conditionally cleavable radioimmunoconjugates: a novel approach for the release of radioisotopes from radioimmunoconjugates
    Craig Beeson
    Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
    Bioconjug Chem 14:927-33. 2003
    ..These studies demonstrate that the cleavable RIC substrate is able to bind to tumor antigens and localize within human tumor xenografts and that accelerated systemic clearance can be induced with beta-lactamase...
  28. ncbi request reprint Efficient cancer therapy with a nanobody-based conjugate
    Virna Cortez-Retamozo
    Department of Molecular and Cellular Interactions, Flanders Interuniversity Institute for Biotechnology, Vrije Universiteit Brussel, Brussels, Belgium
    Cancer Res 64:2853-7. 2004
    ..The easy generation and manufacturing yield of nanobody-based conjugates together with their potent antitumor activity make nanobodies promising vehicles for new generation cancer therapeutics...
  29. ncbi request reprint Secondary mAb--vcMMAE conjugates are highly sensitive reporters of antibody internalization via the lysosome pathway
    Kerry Klussman
    Department of Biochemistry, Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, Washington 98021, USA
    Bioconjug Chem 15:765-73. 2004
    ..This homogeneous screening system is amenable to medium-throughput screening applications and enables the early identification of mAbs capable of intracellular trafficking for drug delivery and release...
  30. ncbi request reprint Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate
    Kevin J Hamblett
    Seattle Genetics, Inc, Bothell, Washington 98021, USA
    Clin Cancer Res 10:7063-70. 2004
    ..To determine the effect of drug loading on antibody-drug conjugate therapeutic potential, we assessed cAC10 antibody-drug conjugates containing different drug-mAb ratios in vitro and in vivo...
  31. ncbi request reprint Efficient elimination of B-lineage lymphomas by anti-CD20-auristatin conjugates
    Che Leung Law
    Seattle Genetics, Inc, 21823 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 10:7842-51. 2004
    ..These data indicate that anti-CD20-based antibody-drug conjugates are effective antitumor agents when prepared with a stable, enzyme-cleavable peptide linkage to highly potent cytotoxic agents such as MMAE...
  32. ncbi request reprint In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate
    Russell J Sanderson
    Seattle Genetics Inc, 21813 30th Drive Southeast, Bothell, WA 98021, USA
    Clin Cancer Res 11:843-52. 2005
    ..These data represent the longest reported drug-linker half-life to date and provide the basis for the pronounced specificity and antitumor activity of cAC10-valine-citrulline-MMAE...
  33. ncbi request reprint Design, synthesis, and in vitro evaluation of dipeptide-based antibody minor groove binder conjugates
    Scott C Jeffrey
    Seattle Genetics, 21823 30th Drive SE, Bothell, WA 98021, USA
    J Med Chem 48:1344-58. 2005
    ..The results provide a general strategy for MGB prodrug design and illustrate the importance of linker hydrophilicity in making nonaggregated, active mAb-MGB conjugates...
  34. ncbi request reprint Novel antitumor prodrugs designed for activation by matrix metalloproteinases-2 and -9
    Toni Kline
    Seattle Genetics, Bothell, Washington 98021, USA
    Mol Pharm 1:9-22. 2004
    ..Our data can be interpreted in light of the current understanding of the structural and mechanistic factors governing MMP-2 and -9 proteolysis...
  35. ncbi request reprint Generation of an intensely potent anthracycline by a monoclonal antibody-beta-galactosidase conjugate
    Michael Y Torgov
    Seattle Genetics, 21823 30th Drive SE, Bothell, Washington 98021, USA
    Bioconjug Chem 16:717-21. 2005
    ..The potential of this enzyme/prodrug combination for cancer therapy is discussed...
  36. ncbi request reprint Chemotherapy delivery issues in central nervous system malignancy: a reality check
    Leslie L Muldoon
    Department of Neurology, Oregon Health and Science University, Portland, and the Veterans Administration Medical Center, OR 97239 3098, USA
    J Clin Oncol 25:2295-305. 2007
    ..This review assesses the current state of knowledge regarding preclinical and clinical pharmacology for brain tumor chemotherapy and evaluates relevant brain tumor pharmacology studies before October 2006...
  37. ncbi request reprint Inhibition of MIF bioactivity by rational design of pharmacological inhibitors of MIF tautomerase activity
    Angeles Dios
    The Picower Institute for Medical Research, Manhasset, NY 11030, USA
    J Med Chem 45:2410-6. 2002
    ..The inhibitory activity of amino acid-benzaldehyde Schiff base-type MIF antagonists is the first step toward a meaningful structure/function analysis of inhibitors of MIF cellular bioactivities...